Login to Your Account



Keryx's Cost-Cutting Plan Follows Sulonex Failure

By Catherine Hollingsworth


Tuesday, April 8, 2008
Keryx BioPharmaceuticals Inc. said it plans to restructure the company, slashing half its workforce, closing three facilities, and delaying or ending several research programs, in the wake of its failed investigative drug Sulonex. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription